心不全患者の酸化ストレスと抗酸化能力に対するリバロキサバの効果の調査
Galia Dilanchian1, Ziba Rezvani Sichani1, Hashem Nayeri1
1Department of Biochemistry, Islamic Azad University, Falavarjan Branch, Isfahan, Iran.
ARYA atherosclerosis
|September 2, 2025
まとめ
マロンディアルデヒド (MDA) 濃度が低く示されたように,リバロキサバン治療は心不全患者の酸化ストレスを有意に減少させた. この研究では,リバロキサバンが
科学分野:
- 心臓病科
- 薬理学について
- 生物化学
背景:
- リバロキサバンは直接的なファクターXA阻害剤で,凝固カスケードを乱します.
- トロンビン媒介反応性酸素種 (ROS) 産生と炎症を減少させることで,酸化ストレスにも影響する可能性があります.
- 心不全患者の酸化ストレスと抗酸化能力に対するリバロキサバンの影響の調査は極めて重要です.
研究 の 目的:
- 酸化ストレスマーカーに対するリバロキサバンの効果を評価する.
- リバロキサバン投与後の抗酸化能力の変化を評価する.
- 心不全における酸化ストレス管理におけるリバロキサバンの役割を理解するために
主な方法:
- ステージBの心不全患者の39人を対象とした前後試験設計.
- 患者は口服リバロキサバン (20 mg/ 日) を2ヶ月間受けた.
- 酸化ストレスと抗酸化バイオマーカー (MDA,ホモシステイン,TAC,PON1,アリレステラーゼ) を治療前と後に測定した.
主要な成果:
- リバロキサバン治療により,マロンディアルデヒド (MDA) 濃度が著しく低下した (P < 0. 001).
- ホモシステイン,アリレステラーゼ,パラオキソナーゼ,または総抗酸化能力 (TAC) の有意な変化は見られなかった (P > 0. 05).
結論:
- リバロキサバンは,MDA値の低下により,心不全患者の酸化ストレスを効果的に軽減します.
- 他の酸化ストレスと抗酸化物質のバイオマーカーへの影響を調べるためにさらなる研究が必要です.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K